Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Crispr Therapeutics AG
A biotech company that turns the CRISPR gene-editing discovery into medicines for serious inherited diseases. Its first approved therapy, Casgevy, treats sickle cell disease and beta-thalassemia by editing a patient's own blood stem cells. Co-founded in 2013 by Emmanuelle Charpentier — one of the scientists who shared the Nobel Prize for discovering CRISPR — along with Rodger Novak and Shaun Foy, the company takes its name directly from the gene-editing system it commercializes.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 3.02 Unregistered Sales of Equity Securities · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
8.01 Other Events
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits